News – Page 109 – Endpoints News

Aura's infrared light-activated drug stops tumor growth and preserves vision in eight eye cancer patients

8 months ago

Moderna plans $1.1B in R&D and program cuts, delays break-even point to 2028

8 months ago

Sanofi buys into radiopharmaceutical field with $110M upfront, going after space held by Novartis

8 months ago

J&J expands Tremfya into IBD with new FDA approval

8 months ago

CVS says it won't correct congressional testimony

9 months ago

Novo Nordisk's longstanding GLP-1 reduced BMI by 7% in children in Phase 3 trial

9 months ago

FDA criticizes AbbVie's 'misleading' ad with Serena Williams

9 months ago

FDA is poised to pull Ocaliva as adcomm documents question post-approval study results

9 months ago

FDA drafts new strategy to boost the use of advanced manufacturing tech

9 months ago

Roche says its Carmot-acquired obesity pill is effective in early study

9 months ago

Xencor’s $175M offering; Viridian to raise $150M

9 months ago

Sanofi opens ‘world first’ modular vaccines and biologics factory in France

9 months ago

Innovent Biologics highlights subgroup of lung cancer patients in early-stage study of bispecific

9 months ago

Former Verily execs launch effort to transform clinical trials

9 months ago

Sanofi, Regeneron prep another FDA submission for Dupixent, this time for a rare skin condition

9 months ago

PanTera raises €93M to ‘radically improve supply’ of actinium for radiotherapeutics

9 months ago

Novo's oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

9 months ago

Radiant Bio snags $35M for antibody platform, with GSK and Regeneron partnerships

9 months ago

GSK discontinues herpes therapeutic vaccine after Phase 2 disappointment

9 months ago

Sanofi, Regeneron to refile Dupixent for skin condition after new study win

9 months ago

BridgeBio ends development of gene therapy for adrenal gland disorder

9 months ago

Adicet follows other cell therapy biotechs in autoimmune pivot

9 months ago

Corrected: Optum’s biosimilar business to go after brand-name Humira, Stelara in 2025

9 months ago

Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs

9 months ago

First page Previous page 106 107 108109110 111 112 Next page Last page